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Abstract
Background Novel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer 
(CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC.
Materials and methods The primary outcome was metastasis-free survival (MFS). The secondary endpoints were overall 
survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time 
(> 6 vs < 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs 0) and concomitant use of 
bone-targeting agent (yes vs no).
Results Pooled analysis of novel hormonal therapies revealed significantly increased MFS compared with placebo (hazard 
ratio (HR): HR = 0.32, 95% CI 0.25–0.41; p < 0.00001). The subgroup analysis showed a statistically significant MFS advan-
tage in favour of men with the lower ECOG performance status. Other secondary endpoints favoured the novel hormonal 
therapies. The relative risk (RR) of grade ≥ 3 adverse events and ≥ 3 hypertension was 1.31 and 1.39, respectively.
Conclusions This study confirmed the efficacy and safety of the novel hormonal therapies in non-metastatic CRPC.
Keywords Prostate cancer · Enzalutamide · Apalutamide · Darolutamide
Introduction
Prostate cancer is one of the main causes of cancer-related 
deaths in men [1]. After initial localized and definitive 
therapy (DT), either with prostatectomy (RP), radiotherapy 
(RT) or both, it is estimated that between 27 and 53% of all 
men treated with DT progress to biochemical recurrence at 
some point in their life [2]. Many of these patients keep on 
to have an increasing elevation of prostate-specific antigen 
(PSA) and are managed with androgen-deprivation therapy 
(ADT) which involves a gonadotropin-releasing hormone 
(GnRH) agonist or antagonist [3]. Unfortunately, failure of 
androgen deprivation therapy is nearly unavoidable and a 
further rising of PSA generally anticipates disease progres-
sion [4] although it is not always accompanied by the pres-
ence of distal metastases. This pathological entity with the 
progressive rising of PSA level on continuous ADT (plus a 
testosterone castrate level) and absence of metastatic lesions 
on imaging diagnostic tools is called non-metastatic castra-
tion-resistant prostate cancer (nmCRPC) [2, 5] and is usu-
ally also characterized by increased amplification or expres-
sion of the androgen receptor gene [6]. The occurrence of 
shorter PSA doubling time of CRPC is associated with a 
shorter time to develop metastasis or death [4, 5] and for 
those with nmCRPC, the treatment goal is to delay the time 
to metastasis. The common metastatic site is the bone and 
is associated with pathologic fracture, pain and spinal cord 
compression [7, 8]. PSA doubling time and baseline PSA 
levels are considered the two main risk factors in developing 
metastasis [9, 10].
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Until recently, no consensus recommendation was accom-
plished for the ideal medication of nmCRPC and observation 
plus first-generation androgen receptor (AR) antagonists, 
such as flutamide or bicalutamide, or with ketoconazole 
or estrogens, was the standard of care [11]; nevertheless, 
none of these therapies was associated with a clear benefit 
in terms of survival [12–14]. Other early phase 3 clinical 
trials assessed additional treatment options for nmCRPC 
but, unfortunately, atrasentan, sodium clodronate and 
zoledronic acid did not show a survival benefit in patients 
with nmCRPC [15–17]. Denosumab, although its reported 
efficacy and MFS benefit, it did not show an improvement 
concerning the overall survival (OS) and finally, it was not 
provided with FDA approval because of its toxic properties 
and not significant improvement in MFS [10, 18].
However, this scenario is destined to change thanks to 
the introduction of novel hormonal therapy based on non-
steroidal drugs that possess the ability to retain antagonism 
in cells overexpressing androgen receptors and have shown 
a significantly longer metastasis-free survival (MFS) time 
compared with placebo [19–21]. In fact, either enzalutamide 
or apalutamide, second-generation androgen receptor antag-
onists, have demonstrated to prolong MFS compared with 
placebo for men with nonmetastatic CRPC [19, 20]. Finally, 
darolutamide, an androgen-receptor antagonist, with a dif-
ferent structure from enzalutamide and apalutamide, was 
confirmed as an active agent in non-metastatic CRPC [21]. 
These novel drugs are changing the treatment landscape for 
nmCRPC patients [17].
In this meta-analysis, the efficacy and safety from rand-
omized controlled trials (RCTs) of novel hormonal therapy 
in patients with non-metastatic CRPC have been in-depth 
analyzed and reported. Finally, possible clinical predictors 
of efficacy have been investigated and future direction treat-
ments are discussed.
Materials and methods
Data retrieval strategies
We conducted a literature-based meta-analysis of RCTs in 
accordance with the preferences for reported items in sys-
tematic reviews and meta-analyses guidelines [22]. Relevant 
publications from PubMed, the Cochrane Library, and the 
American Society of Clinical Oncology (ASCO) Meeting 
were identified using the following search terms: “prostate 
cancer”, “castration-resistant prostate cancer”, “non meta-
static”, “enzalutamide”, “apalutamide”, and “darolutamide” 
(Supplementary files). Publications available in these data-
bases up to March 1, 2019, were analyzed. The search crite-
ria were limited to articles of phase III or phase II RTCs. The 
computer search was supplemented with a manual search of 
the primary studies referenced in all of the retrieved review 
articles. When the results of a study were reported in sub-
sequent analysis, only the most recent and complete ver-
sion was included in this meta-analysis. The protocol for 
this systematic review was registered on the PROSPERO 
International prospective register of systematic reviews 
(CRD42019129545) and is available in full on the website 
at https ://www.crd.york.ac.uk/PROSP ERO.
Inclusion criteria
Two authors screened the studies according to inclusion/
exclusion criteria, the contentious studies were made in con-
sultation with the corresponding author. The studies were 
identified according to the following inclusion criteria: (1) 
participants with non-metastatic CRPC; (2) a novel hormo-
nal therapy as the experimental drug; (3) the presence of a 
control arm for comparison; (4) a primary outcome of MFS 
expressed as the hazard ratio (HR) and secondary outcomes 
of overall survival (OS) expressed as the HR, time to PSA 
progression expressed as the HR and safety expressed as rel-
ative risk (RR). The following exclusion criteria were used: 
(1) insufficient data available to estimate the outcomes; (2) 
animal studies; (3) the size of each arm < 10 participants; 
(4) non-randomized studies. Two authors independently 
extracted the relevant data from the studies.
Quality assessment and statistical analysis
Study quality was assessed using the Jadad 5-item scale, tak-
ing into account randomisation, double-blinding and with-
drawals. The final score ranged from 0 to 5 [23]. In the event 
of disagreements, the consensus was achieved in discussion 
with the corresponding author (GR).
Statistical analysis
The statistical analyses were performed with Revman 5.3. 
The summary estimates were generated using a fixed-effect 
model (Mantel–Haenszel method) or a random-effect model 
(DerSimonian–Laird method) [24, 25] depending on the 
absence or presence of heterogeneity. Statistical heteroge-
neity was assessed with the Q test and the I2 statistic. I2 
values of 25%, 50% and 75% were considered to indicate 
low, moderate and high heterogeneity, respectively [26]. 
When P > 0.1 and I2 < 50%, the fixed-effects model was 
used; otherwise, the random-effects model was used. For the 
time-to-event variables, HRs with 95% confidence intervals 
(CI) were calculated for each study. For the dichotomous 
variables, RRs with 95% CIs were calculated for each study. 
A subgroup analysis was performed to highlight any dif-
ferences between studies according to PSA doubling time 
(> 6 vs < 6 months), ECOG (1 vs 0) and concomitant use 
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of bone-targeting agent (yes vs no). For all the statistical 
analyses, a value of P < 0.05 was regarded as statistically 
significant, and all tests were two-sided.
Results
Literature review and characteristics of the included 
studies
The search yielded 2345 potentially relevant articles. Nine 
hundred and sixty-nine studies were excluded as duplicates. 
After viewing the titles and abstracts of the 1376 remaining 
studies, the full text of 15 studies was retrieved and 3 stud-
ies [19–21] were ultimately included in the analysis (Fig-
ure 1S). A total of 4117 cases were included; among these, 
2694 cases were in the experimental group and 1423 cases in 
the control group. All the studies were randomized, double-
blind, placebo-controlled, phase 3 trials. The characteristics 
of the studies included in the meta-analysis and the defi-
nition of secondary outcomes are summarized in Table 1. 
Median Jadad score was five, confirming a high level of 
quality (Table 1). Due to the small number of trials that were 
included, no publication bias was estimated.
Primary endpoint
After a mean follow-up of 18 months across all included 
studies (Table 2). The pooled analysis revealed that these 
novel hormonal therapies showed a significantly improved 
MFS (HR = 0.32, 95% CI 0.25–0.41; P < 0.00001, I2: 79%; 
Fig. 1). The subsequent subgroup analysis according to PSA 
doubling time (>A total of 4117 cases were 6 vs < 6 months) 
revealed that MFS was significantly improved with a simi-
lar extent (HR = 0.34 vs HR = 0.32; Figure 2S). The pooled 
analysis according to ECOG performance status (1 vs 0) 
revealed that MFS was significantly improved with a greater 
extent in men with ECOG: 0 (HR = 0.30 vs HR = 0.45; Fig-
ure 3S). Finally, the pooled analysis according to the con-
comitant use of bone-targeted agents (yes vs no) revealed 
that MFS was significantly improved with a similar extent 
(HR = 0.36 vs HR = 0.33; Figure 4S).
Secondary endpoints
Data on secondary endpoints are reported in Table 2. The 
pooled analysis revealed that new novel hormonal therapies 
significantly improved OS (HR = 0.74, 95% CI 0.61–0.91; 
P = 0.004) (Fig. 2) compared with placebo. The fixed-effect 
model was used for the absence of heterogeneity (I2 = 0%) 
for this endpoint between the trials. Time to PSA progres-
sion (HR = 0.08, 95% CI 0.05–0.14; P < 0.00001; I2 = 95%) 
was also significantly improved with a novel hormonal agent Ta
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(Fig. 3). The incidence of severe adverse events (grade 3–4) 
ranged from 25 to 45% in the experimental group and 19 
to 34% in the control group, respectively (Table 3). The 
pooled analysis with a random-effects model revealed that 
the RR of a grade ≥ 3 adverse effects was higher with novel 
hormonal therapies compared to placebo (RR = 1.31, 95% 
CI 1.18–1.45; P < 0.001). Other toxicities are reported in 
Table 4. Of note, we found a statistically significant increase 
of RR for hypertension any and ≥ 3 grade and fatigue any 
grade.
Discussion
Although the treatment scenario of metastatic CRPC has 
been recently revolutionized by the approval of several 
agents able to increase survival [27–29], none of these 
agents is curative and the median survival is around 36 
months [30]. Therefore, in the specific setting of non-met-
astatic CRPC, the use of novel hormonal agents to delay 
the time to metastasis may prolong survival and cancer-
related complications [31]. To the best of our knowledge, 
Table 2  Data on metastasis-free survival, median treatment duration 
and a median follow-up of the included studies
MFS metastasis-free survival, OS overall survival, HR hazard ratio, 
NR not reported, E enzalutamide, PL placebo, BIC bicalutamide, D 
darolutamide, APA apalutamide
Study Median MFS 
(months)
Median treatment 
duration (months)
Median 
follow-up 
(months)
ARAMIS 40.4 vs 18.4 14.8 (D) 17.9
D vs PL HR: 0.41 11 (PL)
PROSPER 36.6 vs 14.7 18.4 (E) 18.5 (E)
E vs PL HR: 0.29 11.1 (PL) 15.1 (PL)
SPARTAN 40.5 vs 16.2 NR 20.3
APA vs PL HR: 0.28
Fig. 1  Forest plots of hazard ratios (HRs) for metastasis-free survival (MFS) comparing novel hormonal therapy to placebo
Fig. 2  Forest plots of hazard ratios (HRs) for overall survival (OS) comparing novel hormonal therapy to placebo
Fig. 3  Forest plots of hazard ratios (HRs) for time to PSA progression comparing novel hormonal therapy to placebo
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the present study is the first literature-based meta-analysis 
of 3 RCTs with more than 4000 patients that summarizes 
the efficacy and safety of novel hormonal therapies for the 
treatment of non-metastatic CRPC. Our results revealed a 
reduction in the risk of time to development of metastasis 
in almost 70% of patients and a reduction in death and time 
to PSA progression in 26% and more than 90% of patients 
respectively. Of note, we showed that novel hormonal agents 
prolong OS in a statistically significant fashion, and although 
median OS (still not reached in all experimental arms) and 
the short follow-up preclude from definitive conclusions, we 
confirm the use of novel hormonal agents to prolong survival 
of non-metastatic CRPC. The absence of heterogeneity fur-
ther supports this data.
Interestingly, the planned subgroup analysis according 
to PSA doubling time (> 6 vs < 6 months), ECOG (1 vs 
0) and concomitant use of bone-targeting agent (yes vs no) 
showed no consistent difference in terms of MFS regard-
less of the PSA doubling time and the use of concomitant 
bone-targeting agents. Conversely, when patients with 
ECOG performance status of 0 have been compared to 
patients with ECOG performance status of 1 a statistically 
significant MFS advantage has been found with novel hor-
monal agents in favour of men with the lower ECOG per-
formance status (HR: 0.30 vs 0.45 respectively, Figure 3S). 
The absence of heterogeneity for ECOG:0 subgroup further 
supports these data. Therefore, further investigations for the 
subgroup of patients with ECOG > 0 are awaited to define 
the optimal role of novel hormonal agents in non-metastatic 
CRPC.
According to toxicity, the pooled analysis with a fixed-
effects model revealed that the incidence of a grade ≥ 3 
adverse event was moderately higher with novel hormonal 
therapies (RR = 1.31). In addition, although an increase in 
adverse events associated with death has been observed, this 
result did not reach statistical significance. Therefore, our 
data confirm the safety profile of novel hormonal therapies 
[27, 30–32]. However, in line with previous studies [33], we 
Table 3  Secondary outcomes of 
the included studies
MFS metastasis-free survival, OS overall survival, HR hazard ratio, NR not reported, E enzalutamide, A 
abiraterone, P prednisone, PL placebo, BIC bicalutamide
Study Median OS (months) Median time to PSA 
progression (months)
Adverse event lead-
ing to death (%)
Any adverse 
event ≥ 3 (%)
ARAMIS Not reached 33.2 vs 7.3 3.9 vs 3.2 24.7 vs 19.5
D vs PL HR 0.71 HR 0.13
PROSPER Not reached 37.2 vs 3.9 3 vs 1 31 vs 23
E vs PL HR 0.80 HR 0.07
SPARTAN Not reached vs 39 Nor reached vs 3.7 1.2 vs 0.3 45.1 vs 34.2
APA vs PL HR 0.70 HR 0.06
Table 4  Adverse events
Statistically significant values are in bold
HR hazard ratio, CI confidence interval
HR 95% CI P value I2 (%) P value Model
Any adverse event
Grade 1–4
1.08 1.02–1.14 0.01 79 0.008 Random
Any adverse event
Grade ≥ 3
1.31 1.18–1.45 < 0.001 0 0.93 Fixed
Serious adverse event
Grade 1–4
1.21 1.07–1.37 0.002 0 0.38 Fixed
Adverse event leading to discon-
tinuation of the trial regimen
1.30 1.05–1.62 0.02 35 0.22 Fixed
Adverse event leading to death 2.67 0.79–9.02 0.11 70 0.04 Random
Fatigue
Grade 1–4
1.69 1.19–2.39 0.003 82 0.004 Random
Fatigue
Grade ≥ 3
1.85 0.38–9.14 0.45 71 0.03 Random
Hypertension
Grade 1–4
1.50 1.03–2.18 0.03 70 0.04 Random
Hypertension
Grade ≥ 3
1.39 1.07–1.81 0.01 13 0.32 Fixed
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reported an increase in the RR of hypertension > 3. Interest-
ingly, our meta-analysis is in line with another recent paper 
by Di Nunno et al. [34].
The present meta-analysis has several limitations. There 
were only three studies, and these studies exhibited very 
high levels of heterogeneity for some of the endpoints. It 
should be noted that no active comparator was used in all the 
evaluated trials. Furthermore, only two secondary endpoints 
were not evaluated in our meta-analysis and the adverse 
event analysis was limited to fatigue and Hypertension 
with different versions of Common Terminology Criteria 
for Adverse Events (CTCAE) used across the three studies. 
Finally, our meta-analysis was based on the literature rather 
than on individual patients’ data, however, it was a large 
sample size with more than 4117 patients in total (2694 in 
the experimental arm).
Conclusions
Currently, the use of novel hormonal agents has been widely 
validated for metastatic CRPC in the chemotherapy-naïve 
and post-chemotherapy settings. Our literature-based meta-
analysis supports the existing evidence to target the andro-
genic pathway for also non-metastatic CRPC, further studies 
are awaited to discover predictive markers of efficacy and the 
best candidate for this approach.
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